echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > J & J's $1.1 billion acquisition of three anti HCV pipelines to beat Gillette and Aberdeen

    J & J's $1.1 billion acquisition of three anti HCV pipelines to beat Gillette and Aberdeen

    • Last Update: 2015-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: data source Huitong on May 20, 2015, Johnson & Johnson spent $1.1 billion to acquire three anti HCV products under research from Achillion The down payment was $225 million and the milestone cost totaled $905 million According to the purchase agreement, the three products are ach-3102, an NS5A inhibitor, sovaprevir, an NS3 / 4A protease inhibitor, and ach-3422, an NS5B polymerase inhibitor, which are in phase I clinical phase Among them, ach-3102 was approved by FDA as a rapid approval project In the future, Yang Sen, a pharmaceutical company under Johnson & Johnson, will be responsible for the development and investment of new drugs Johnson & Johnson does not have no products in the field of hepatitis C At present, an oral NS3 / 4 protease inhibitor, olysio, is on the market However, in order to compete with the popular products on the market (such as Gilead, which won the market with the compound preparation harvoni, and Alberta, which launched the combination of viekirax and exviera), Johnson & Johnson needs to enrich its product line In the first quarter of 2015, olysio's growth in the United States declined, with sales of only US $98 million, compared with us $291 million in 2014; in the first quarter of 2015, global sales also fell by a third to US $234 million The acquisition of three products under development from Achillion may help Johnson beat Gillette and Aberdeen The current clinical results show that Johnson & Johnson's combination of drugs can clear hepatitis C virus within 6 weeks, which is slightly better than the current opponents who clear hepatitis C virus within 8 weeks.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.